{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:56:08Z","timestamp":1790272568680,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["205646"],"award-info":[{"award-number":["205646"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["110751"],"award-info":[{"award-number":["110751"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["115471"],"award-info":[{"award-number":["115471"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["114055"],"award-info":[{"award-number":["114055"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["LBSL02"],"award-info":[{"award-number":["LBSL02"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["KJPB12.028"],"award-info":[{"award-number":["KJPB12.028"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["17OKG04"],"award-info":[{"award-number":["17OKG04"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Netherlands Organization for Scientific Research","award":["90713460"],"award-info":[{"award-number":["90713460"]}]},{"name":"University of Salamanca"},{"name":"Dutch Kidney Foundation and Netherlands Organization for Scientific Research"},{"name":"Aurinia Pharmaceuticals"},{"name":"Novartis and KezarBio"},{"name":"Fishawack Indicia Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Autoreactive memory B cells (MBCs) contribute to chronic and progressive courses in autoimmune diseases like SLE. The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and LN, is generally attributed to depletion of activated na\u00efve B cells and inhibition of B-cell\u00a0activation. BEL\u2019s effect on MBCs is currently unexplained. We performed an in-depth cellular and transcriptomic analysis of BEL\u2019s impact on the blood MBC compartment in patients with SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective meta-analysis was conducted, pooling flow cytometry data from four randomized trials involving 1245 patients with SLE treated with intravenous BEL or placebo. Then, extensive MBC phenotyping was performed using high-sensitivity flow cytometry in patients with mild\/moderate SLE and severe SLE\/LN treated with subcutaneous BEL. Finally, transcriptomic characterization of surging MBCs was performed by single-cell RNA sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In BEL-treated patients, a significant increase in circulating MBCs, in a broad range of MBC subsets, was established at week 2, gradually returning to baseline by week 52. The increase was most prominent in patients with higher SLE disease activity, serologically active patients and patients aged \u226418\u2009years. MBCs had a non-proliferating phenotype with a prominent decrease in activation status and downregulation of numerous migration genes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Upon BEL initiation, an increase of MBCs was firmly established. In the small cohort investigated, circulating MBCs were de-activated, non-proliferative and demonstrated characteristics of disrupted lymphocyte trafficking, expanding on our understanding of the therapeutic mechanism of B-cell-activating factor inhibition by BEL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT00071487, NCT00410384, NCT01632241, NCT01649765, NCT03312907, NCT03747159.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae286","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:30:28Z","timestamp":1716395428000},"page":"2387-2398","source":"Crossref","is-referenced-by-count":13,"title":["Disruption of memory B-cell\u00a0trafficking by belimumab in patients with systemic lupus erythematosus"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-4077","authenticated-orcid":false,"given":"Eline J","family":"Arends","sequence":"first","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine\u2014Section Nephrology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-8883","authenticated-orcid":false,"given":"Mihaela","family":"Zlei","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Centre , Leiden, The Netherlands"},{"name":"Medical Laboratory, Department of Flow Cytometry, Regional Institute of Oncology , Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Tipton","sequence":"additional","affiliation":[{"name":"Lowance Centre for Human Immunology, Emory University School of Medicine , Atlanta, GA, USA"},{"name":"Department of Medicine, Division of Rheumatology, Emory University , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Cotic","sequence":"additional","affiliation":[{"name":"Clinical Statistics, GSK , Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zgjim","family":"Osmani","sequence":"additional","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine\u2014Section Nephrology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenna J","family":"de Bie","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia W A","family":"Kamerling","sequence":"additional","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine\u2014Section Nephrology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"van Maurik","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Experimental Medicine, GSK , Hertfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dimelow","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modelling and Simulation, GSK , Hertfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Irene","family":"Gregan","sequence":"additional","affiliation":[{"name":"Clinical Science Immunology, GSK , Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma Lynn","family":"Fox","sequence":"additional","affiliation":[{"name":"Clinical Development, GSK , Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton J","family":"Rabelink","sequence":"additional","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine\u2014Section Nephrology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Roth","sequence":"additional","affiliation":[{"name":"Research and Development, GSK , Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Sanz","sequence":"additional","affiliation":[{"name":"Lowance Centre for Human Immunology, Emory University School of Medicine , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques J M","family":"van Dongen","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca , Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Kooten","sequence":"additional","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine\u2014Section Nephrology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y K Onno","family":"Teng","sequence":"additional","affiliation":[{"name":"Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine\u2014Section Nephrology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"2024090322075716300_keae286-B1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/0961203312471576","article-title":"B cell biology: implications for treatment of systemic lupus erythematosus","volume":"22","author":"Anolik","year":"2013","journal-title":"Lupus"},{"key":"2024090322075716300_keae286-B2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"2024090322075716300_keae286-B3","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B4","doi-asserted-by":"crossref","first-page":"e5456","DOI":"10.1371\/journal.pone.0005456","article-title":"Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells","volume":"4","author":"Rauch","year":"2009","journal-title":"PLoS One"},{"key":"2024090322075716300_keae286-B5","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J Rheumatol"},{"key":"2024090322075716300_keae286-B6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B8","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B9","doi-asserted-by":"crossref","first-page":"e0128269","DOI":"10.1371\/journal.pone.0128269","article-title":"Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response","volume":"10","author":"Adlowitz","year":"2015","journal-title":"PLoS One"},{"key":"2024090322075716300_keae286-B10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B12","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2024090322075716300_keae286-B13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2024090322075716300_keae286-B14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.13013","article-title":"Plasma cell survival: the intrinsic drivers, migratory signals, and extrinsic regulators","volume":"303","author":"Nguyen","year":"2021","journal-title":"Immunol Rev"},{"key":"2024090322075716300_keae286-B15","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2024090322075716300_keae286-B16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024090322075716300_keae286-B17","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024090322075716300_keae286-B18","doi-asserted-by":"crossref","first-page":"e025687","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"key":"2024090322075716300_keae286-B19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s13063-022-06874-w","article-title":"Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial","volume":"23","author":"van Schaik","year":"2022","journal-title":"Trials"},{"key":"2024090322075716300_keae286-B20","author":"ClinicalTrials.gov","year":"2019"},{"key":"2024090322075716300_keae286-B21","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jaci.2018.02.017","article-title":"Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood","volume":"141","author":"Blanco","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024090322075716300_keae286-B22","doi-asserted-by":"crossref","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"2024090322075716300_keae286-B23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"2024090322075716300_keae286-B24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024090322075716300_keae286-B25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \"peptibody\" blisibimod (AMG 623\/A-623): results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024090322075716300_keae286-B26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024090322075716300_keae286-B27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.coi.2006.03.013","article-title":"B cell recognition of membrane-bound antigen: an exquisite way of sensing ligands","volume":"18","author":"Carrasco","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"2024090322075716300_keae286-B28","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-081232","article-title":"BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells","volume":"111","author":"Badr","year":"2008","journal-title":"Blood"},{"key":"2024090322075716300_keae286-B29","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"2024090322075716300_keae286-B30","doi-asserted-by":"crossref","first-page":"R1001","DOI":"10.1186\/ar1776","article-title":"Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"7","author":"Henneken","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2024090322075716300_keae286-B31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"key":"2024090322075716300_keae286-B32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri2637","article-title":"Dysregulation of germinal centres in autoimmune disease","volume":"9","author":"Vinuesa","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2024090322075716300_keae286-B33","doi-asserted-by":"crossref","first-page":"e127885","DOI":"10.1172\/jci.insight.127885","article-title":"Patterns of ANA+ B cells for SLE patient stratification","volume":"4","author":"Suurmond","year":"2019","journal-title":"JCI Insight"},{"key":"2024090322075716300_keae286-B34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.immuni.2018.03.027","article-title":"T follicular helper cell-germinal center B cell interaction strength regulates entry into plasma cell or recycling germinal center cell fate","volume":"48","author":"Ise","year":"2018","journal-title":"Immunity"},{"key":"2024090322075716300_keae286-B35","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.4049\/jimmunol.1101542","article-title":"EBI2 operates independently of but in cooperation with CXCR5 and CCR7 to direct B cell migration and organization in follicles and the germinal center","volume":"187","author":"Gatto","year":"2011","journal-title":"J Immunol"},{"key":"2024090322075716300_keae286-B36","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.4049\/jimmunol.154.11.5746","article-title":"Regulation of germinal center B cell differentiation. Role of the human APO-1\/Fas (CD95) molecule","volume":"154","author":"Lagresle","year":"1995","journal-title":"J Immunol"},{"key":"2024090322075716300_keae286-B37","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"key":"2024090322075716300_keae286-B38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol Sci"},{"key":"2024090322075716300_keae286-B39","doi-asserted-by":"crossref","first-page":"566732","DOI":"10.3389\/fimmu.2020.566732","article-title":"Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients","volume":"11","author":"van Dam","year":"2020","journal-title":"Front Immunol"},{"key":"2024090322075716300_keae286-B40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B41","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar2789","article-title":"Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis","volume":"11","author":"Rehnberg","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2024090322075716300_keae286-B42","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology"},{"key":"2024090322075716300_keae286-B43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024090322075716300_keae286-B44","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","article-title":"Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024090322075716300_keae286-B45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"2024090322075716300_keae286-B46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024090322075716300_keae286-B47","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms21228470","article-title":"Targeting NF-kappaB-inducing kinase (NIK) in immunity, inflammation, and cancer","volume":"21","author":"Pflug","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024090322075716300_keae286-B48","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/0961203319885447","article-title":"Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures","volume":"28","author":"Brohawn","year":"2019","journal-title":"Lupus"},{"key":"2024090322075716300_keae286-B49","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"2024090322075716300_keae286-B50","doi-asserted-by":"crossref","first-page":"215308","DOI":"10.6064\/2012\/215308","article-title":"B cell in autoimmune diseases","volume":"2012","author":"Hampe","year":"2012","journal-title":"Scientifica"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae286\/58101213\/keae286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2387\/59007363\/keae286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2387\/59007363\/keae286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T10:46:13Z","timestamp":1725446773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2387\/7679676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,22]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae286","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,22]]}}}